Predict your next investment

HEALTHCARE | Drug Development
ganlee.com

See what CB Insights has to offer

Founded Year

1998

Stage

IPO | IPO

Total Raised

$449.52M

Date of IPO

6/29/2020

About Gan & Lee Pharmaceuticals

Gan & Lee Pharmaceuticals (603087.SH) is a biotechnology company in China engaged in the development, manufacturing, and commercialization of human therapeutics. Gan & Lee has fully integrated capabilities in research and development, manufacturing, commercial operations and product distribution. Its top line products recombinant human insulin and insulin analogs meet EP and USP quality standards, and it is the only local company which owns human insulin analogue in China.

Gan & Lee Pharmaceuticals Headquarter Location

No. 8 Jingsheng North 3rd Street Golden Bridge Science Industrial Base, Zhongguancun Science Park, Tongzhou District

Beijing, Beijing, 101102,

China

Latest Gan & Lee Pharmaceuticals News

Gan & Lee Pharmaceuticals to present data at the 57th Annual European Association for the Study of Diabetes Meeting

Sep 11, 2021

PRNewsWire India BEIJING and BRIDGEWATER, N. J., Sept. 9, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is excited to present positive data from five abstracts which will be featured as short oral discussions at the 57th Annual European Association for the Study of Diabetes (EASD) Meeting. The meeting will be held virtually from September 27th – October 1st, 2021.The following new data will be presented on September 30th, 2021, 11:45 – 13:15 CEST: * Novel GLP-1 analogue, GZR18: a preclinical evaluation in type 2 diabetes models * Phase 3 confirmatory study comparing efficacy and safety of proposed biosimilar and reference insulin aspart, combined with metformin, in patients with diabetesIn addition, recent results from our encore Phase 1 clinical trials will also be presented on September 30th, 2021, 11:45 – 13:15 CEST: * Proposed biosimilar insulin aspart (GL-ASP) shows pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to US-licenced and EU-authorised insulin aspart * Proposed biosimilar insulin lispro (GL-LIS) shows pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to US-licenced and EU-authorised insulin lispro  * Proposed biosimilar insulin glargine (GL-GLA) shows pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to US-licenced and EU-authorised insulin glargineThe data that will be presented at the EASD Annual Meeting, are important milestones for the clinical development programs at Gan & Lee. Furthermore, the abstracts mentioned above demonstrate Gan & Lee's dedication to providing solutions for patients with diabetes. "We are pleased to have all five abstracts published by the EASD as we continue to seek scientific solutions for diabetes care", said Michelle Mazuranic, Head of Global Medical Affairs. The presentation numbers for GZR18, GL-ASP (Phase 3 in China), GL-ASP (Phase 1), GL-LIS, and GL-GLA are 463, 513, 510, 514, and 511, respectively.About Gan & LeeGan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin®30), and one human insulin injection approved in China - mixed protamine human insulin injection (30R) (Similin®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®).In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and working on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics. For more information, please contact us at investorrelations@ganlee.us.References: * Leona Plum- Mörschel, et. al. Proposed biosimilar insulin aspart (GL-ASP) shows pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to US-licenced and EU-authorised insulin aspart. Diabetes. June 22, 2021. * Eric Zijlstra, et. al. Proposed biosimilar insulin lispro (GL-LIS) shows pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to US-licenced and EU-authorised insulin lispro. Diabetes. June 22, 2021. * Tim Heise, et. al. Proposed biosimilar insulin glargine (GL-GLA) shows pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to US-licenced and EU-authorised insulin glargine. Diabetes. June 22, 2021.Gina Antonucci, #: 888-288-5395, investorrelations@ganlee.us   Advertisements

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Gan & Lee Pharmaceuticals

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Gan & Lee Pharmaceuticals in 1 CB Insights research brief, most recently on Jun 24, 2021.

Expert Collections containing Gan & Lee Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Gan & Lee Pharmaceuticals is included in 3 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D

Diabetes

1,750 items

Gan & Lee Pharmaceuticals Patents

Gan & Lee Pharmaceuticals has filed 4 patents.

The 3 most popular patent topics include:

  • Cell cycle
  • Experimental cancer drugs
  • Proteins
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/28/2016

8/17/2021

Cell cycle, Transcription factors, Proteins, Protein kinase inhibitors, Experimental cancer drugs

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/28/2016

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/17/2021

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Cell cycle, Transcription factors, Proteins, Protein kinase inhibitors, Experimental cancer drugs

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Gan & Lee Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Gan & Lee Pharmaceuticals Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.